Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-018239
Filing Date
2022-09-08
Accepted
2022-09-08 16:06:17
Documents
45
Period of Report
2022-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20220731.htm   iXBRL 10-Q 1422172
2 EX-31.1 kalv-ex31_1.htm EX-31.1 23418
3 EX-31.2 kalv-ex31_2.htm EX-31.2 20210
4 EX-32.1 kalv-ex32_1.htm EX-32.1 15014
  Complete submission text file 0000950170-22-018239.txt   4706296

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20220731_pre.xml EX-101.PRE 145595
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20220731_lab.xml EX-101.LAB 221842
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20220731.xsd EX-101.SCH 24154
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kalv-20220731_def.xml EX-101.DEF 43169
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kalv-20220731_cal.xml EX-101.CAL 44050
39 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20220731_htm.xml XML 882390
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 221233896
SIC: 2834 Pharmaceutical Preparations